The Swedish government and GE Healthcare are opening Testa Center – an innovation center in Uppsala, Sweden, to boost the commercialization of new technologies and support manufacturing capabilities in the life sciences sector.
The Testa Center houses four bioprocessing laboratories with GE Healthcare technologies for testing new discoveries for the production of biopharmaceuticals, the world’s fastest-growing class of medicines .
The Swedish government, which has invested around €10 million in Testa Center and has identified life sciences as one of its top five partnership programs, is striving to increase collaboration between the public sector, business and academia to strengthen the country’s competitiveness and innovation capability. Earlier this year, the government opened an office that is fully dedicated to life sciences.
GE Healthcare, a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, has invested around €4.5 million in the center.
Swedish biotechnology company BioLamina is the first company to run a project at Testa Center. Biolamina develops and manufactures protein-based reagents, Biolaminins used to create reliable and robust processes to develop therapeutic cells from stem cells. The company recently entered into a collaboration with the pharmaceutical company Novo Nordisk to support the development of new cell therapies targeting Parkinson’s disease, heart failure and loss of vision. BioLamina will use Testa Center to scale-up its production capacity, helping it deliver more reagents to its global customer base.
Testa Center is a testbed open to academia, start-ups and industry. It is purpose-built for verifying digital, technical and biological innovations in an authentic production setting.